Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of ...
At the 2026 American Academy of Dermatology Annual Meeting in Denver, Kenvue’s Neutrogena, Aveeno and Rogaine brands ...
Building on insights from last year, experts across sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting ...
Incyte’s phase 3 STOP-HS data show that povorcitinib improved symptoms of moderate to severe hidradenitis suppurativa in most ...
As the 2026 American Academy of Dermatology (AAD) annual meeting approaches, MedPage Today is offering a preview of an ...
For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant ...
From teledermatology billing to rural outreach and transplant advances, new studies and presentations reveal shifts in access ...
CONTINUOUS secukinumab treatment showed sustained hidradenitis suppurativa lesion control through 4 years in responding patients. Sustained Lesion Improvements with Secukinumab. N ...
AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research sessionAcross the COAST 1, ...
PATIENTS with moderate-to-severe atopic dermatitis showed generally low long-term upadacitinib safety event rates across ages. Upadacitinib Safety in Atopic Dermatitis Across Age ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
LEO Pharma A/S, a global leader in medical dermatology, today announced the presentation of new post-hoc analyses of 12‑month real‑world data from the TRACE study of tralokinumab, at the 2026 American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results